Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints

The Origin of Skin Dendritic Cell Network and Its Role in Psoriasis

(2017) Tae-Gyun Kim et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Lessons learned from twins in autoimmune and chronic inflammatory diseases

(2017) Elena Generali et al.   JOURNAL OF AUTOIMMUNITY

Psoriasis or not? Review of 51 clinically confirmed cases reveals an expanded histopathologic spectrum of psoriasis

(2017) Thinh Chau et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries

(2017) M. Augustin et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

(2017) Kristian Reich et al.   LANCET

Psoriatic Arthritis

(2017) Christopher T. Ritchlin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

(2017) Philip Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

(2017) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study

(2017) Arthur Kavanaugh et al.   ARTHRITIS CARE & RESEARCH

Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)

(2016) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2016) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)

(2016) Vibeke Strand et al.   ANNALS OF THE RHEUMATIC DISEASES

Psoriasis and autoimmunity

(2016) Michael Sticherling   AUTOIMMUNITY REVIEWS

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints

(2016) Ugo Fiocco et al.   CLINICAL RHEUMATOLOGY

Malignancy incidence in patients with psoriatic arthritis: a comparison cohort-based incidence study

(2016) Katelynn M. Wilton et al.   CLINICAL RHEUMATOLOGY

Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials

(2016) Bruce Strober et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS)

(2016) M. Sala et al.   JOURNAL OF CONTROLLED RELEASE

HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up

(2016) Marina Talamonti et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials

(2016) Alexandra B. Kimball et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation

(2016) Giulio Cavalli et al.   RHEUMATOLOGY

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?

(2016) Laura C. Coates et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

(2016) Désirée van der Heijde et al.   Arthritis & Rheumatology

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

(2016) Laura C. Coates et al.   Arthritis & Rheumatology

PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus

(2015) John Bowes et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors

(2015) W Gao et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

(2015) R.G. Langley et al.   BRITISH JOURNAL OF DERMATOLOGY

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

(2015) K. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Dermal γδ T cells – What have we learned?

(2015) Rebecca L. O’Brien et al.   CELLULAR IMMUNOLOGY

What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?

(2015) Lihi Eder et al.   CURRENT OPINION IN RHEUMATOLOGY

Towards a Stratified Targeted Approach with Biologic Treatments in Rheumatoid Arthritis: Role of Synovial Pathobiology

(2015) Elisa Astorri et al.   CURRENT PHARMACEUTICAL DESIGN

Secukinumab: First Global Approval

(2015) Mark Sanford et al.   DRUGS

The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against Candida infections

(2015) M. Jaeger et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

IL-37 Alleviates Rheumatoid Arthritis by Suppressing IL-17 and IL-17–Triggering Cytokine Production and Limiting Th17 Cell Proliferation

(2015) Liang Ye et al.   JOURNAL OF IMMUNOLOGY

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody

(2015) Sanjaya Singh et al.   mAbs

IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction

(2015) Claudia A Nold-Petry et al.   NATURE IMMUNOLOGY

The IL-23–IL-17 axis in inflammatory arthritis

(2015) Erik Lubberts   Nature Reviews Rheumatology

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Epidemiology of Psoriatic Arthritis

(2015) Alexis Ogdie et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis

(2015) Juan D. Cañete et al.   ARTHRITIS RESEARCH & THERAPY

Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis

(2015) John Bowes et al.   Nature Communications

Comparative Genomic Profiling of Synovium Versus Skin Lesions in Psoriatic Arthritis

(2015) Jennifer Belasco et al.   Arthritis & Rheumatology

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Diagnosis and classification of psoriasis

(2014) Smriti K. Raychaudhuri et al.   AUTOIMMUNITY REVIEWS

Interleukin (IL)-17A, F and AF in inflammation: a study in collagen-induced arthritis and rheumatoid arthritis

(2014) S. Sarkar et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model

(2014) Qingcui Li et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

(2014) Howard Sofen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Pharmacologic Inhibition of ROR t Regulates Th17 Signature Gene Expression and Suppresses Cutaneous Inflammation In Vivo

(2014) J. Skepner et al.   JOURNAL OF IMMUNOLOGY

IL-37 Ameliorates the Inflammatory Process in Psoriasis by Suppressing Proinflammatory Cytokine Production

(2014) X. Teng et al.   JOURNAL OF IMMUNOLOGY

LC–MS Metabolomics of Psoriasis Patients Reveals Disease Severity-Dependent Increases in Circulating Amino Acids That Are Ameliorated by Anti-TNFα Treatment

(2014) Muhammad Anas Kamleh et al.   JOURNAL OF PROTEOME RESEARCH

Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review

(2014) M. Rouzaud et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

(2014) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crossreactive Autoantibodies Directed against Cutaneous and Joint Antigens Are Present in Psoriatic Arthritis

(2014) Marzia Dolcino et al.   PLoS One

Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosis

(2014) Bogusław Nedoszytko et al.   Postepy Dermatologii i Alergologii

Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?

(2014) Lisa GM van Baarsen et al.   ARTHRITIS RESEARCH & THERAPY

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Is chronic plaque psoriasis triggered by microbiota in the skin?

(2013) L. Fry et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1

(2013) P. Rich et al.   BRITISH JOURNAL OF DERMATOLOGY

New learnings on the pathophysiology of RA from synovial biopsies

(2013) Costantino Pitzalis et al.   CURRENT OPINION IN RHEUMATOLOGY

IL-22, not simply a Th17 cytokine

(2013) Sascha Rutz et al.   IMMUNOLOGICAL REVIEWS

Dermal Clusters of Mature Dendritic Cells and T Cells Are Associated with the CCL20/CCR6 Chemokine System in Chronic Psoriasis

(2013) Tae-Gyun Kim et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Th17 and Th22 cells in psoriatic arthritis and psoriasis

(2013) Helen Benham et al.   ARTHRITIS RESEARCH & THERAPY

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway

(2012) Saba Alzabin et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunomodulation in psoriatic arthritis: Focus on cellular and molecular pathways

(2012) Maria Sole Chimenti et al.   AUTOIMMUNITY REVIEWS

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

(2012) A.B. Kimball et al.   BRITISH JOURNAL OF DERMATOLOGY

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

(2012) R.G. Langley et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells

(2012) Jonathan P Sherlock et al.   NATURE MEDICINE

IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist

(2012) F. L. van de Veerdonk et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Functional role of IL-22 in psoriatic arthritis

(2012) Anupam Mitra et al.   ARTHRITIS RESEARCH & THERAPY

Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features

(2012) Raquel Celis et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

(2011) B.E. Strober et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

(2011) A.B. Gottlieb et al.   BRITISH JOURNAL OF DERMATOLOGY

Interleukin-23: as a drug target for autoimmune inflammatory diseases

(2011) Chunlei Tang et al.   IMMUNOLOGY

Cutaneous immunosurveillance by self-renewing dermal γδ T cells

(2011) Nital Sumaria et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis

(2011) Kenneth B. Gordon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis

(2011) Kristian Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease

(2010) Reiko M. Onishi et al.   IMMUNOLOGY

Carriers of Rare Missense Variants in IFIH1 Are Protected from Psoriasis

(2010) Yonghong Li et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

IL-23 induces receptor activator of NF-κB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-κB signal pathways

(2009) Xia Li et al.   IMMUNOLOGY LETTERS

Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling

(2009) Stefanie Eyerich et al.   JOURNAL OF CLINICAL INVESTIGATION

The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis

(2009) Antonella Di Cesare et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Psoriatic arthritis: from pathogenesis to therapy

(2009) Oliver FitzGerald et al.   ARTHRITIS RESEARCH & THERAPY

Ectopic Lymphoid Structures Support Ongoing Production of Class-Switched Autoantibodies in Rheumatoid Synovium

(2009) Frances Humby et al.   PLOS MEDICINE

Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis

(2008) F Brentano et al.   ANNALS OF THE RHEUMATIC DISEASES

Cardiovascular morbidity in psoriatic arthritis

(2008) D D Gladman et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment recommendations for psoriatic arthritis

(2008) C T Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

(2008) Alexa B. Kimball   ARCHIVES OF DERMATOLOGY

IL-22 is required for Th17 cell–mediated pathology in a mouse model of psoriasis-like skin inflammation

(2008) Hak-Ling Ma et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Induction and effector functions of TH17 cells

(2008) Estelle Bettelli et al.   NATURE